Eckert & Ziegler SE will participate in the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, 14 January 2026, at the Westin St. Francis in San Francisco. Dr Harald Hasselmann, CEO of Eckert & Ziegler SE, will present the company at 17:15 PST, with the presentation available as an audio livestream on the company's website at https://www.ezag.com/investors/presentations/. The recording will remain accessible for approximately 30 days following the event.
This participation matters because the J.P. Morgan Healthcare Conference represents the largest and most influential healthcare investment symposium globally, attracting institutional investors, industry executives, and analysts who shape capital allocation decisions across the medical sector. Eckert & Ziegler's presence signals its position as a significant player in the specialized field of nuclear medicine and radiation therapy components, where the company employs over 1,000 professionals and offers comprehensive services from early development to contract manufacturing and distribution for the radiopharmaceutical industry.
The implications extend beyond investor relations to the broader healthcare landscape. As a TecDAX-listed company (ISIN DE0005659700), Eckert & Ziegler's performance and strategic direction influence market perceptions of the entire radiopharmaceutical sector. The company's focus on isotope-related components addresses critical needs in cancer treatment and diagnostic imaging, areas experiencing rapid technological advancement and increasing demand due to aging populations worldwide.
For the medical industry, developments in radiopharmaceuticals represent a frontier in targeted cancer therapies that minimize damage to healthy tissues compared to conventional treatments. Eckert & Ziegler's work supports this medical revolution by providing essential components and manufacturing capabilities. The company's presentation at this premier conference offers transparency about technological progress, regulatory developments, and market expansion strategies that affect healthcare providers, patients awaiting advanced treatments, and competing firms in the medical technology space.
The global impact connects to public health outcomes, as innovations in nuclear medicine contribute to earlier disease detection and more effective treatments. Investors monitoring the conference gain insights into how specialized medical technology companies like Eckert & Ziegler navigate complex regulatory environments, supply chain challenges, and international expansion while maintaining the precision required for medical applications. The availability of the presentation recording ensures broader access to this information beyond the conference attendees.
